Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Aktis Oncology, Inc. (Nasdaq: AKTS), a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. While specific SEC filings are not listed in the provided information, a Nasdaq-listed issuer such as Aktis Oncology would typically use SEC reports to describe its business, pipeline, risks, and capital structure in more detail.
Annual and quarterly reports, such as Forms 10-K and 10-Q when available, generally provide narrative and financial disclosure about companies like Aktis Oncology. For a clinical-stage radiopharmaceutical company, these documents often include descriptions of its miniprotein radioconjugate platform, targeted tumor types, clinical development plans, and factors that could affect its research and development activities.
Registration statements, such as the Form S-1 that Aktis Oncology reports was declared effective in connection with its initial public offering, offer additional background on the company’s history, founding, and the structure of its capital raising transactions. Aktis Oncology has stated that its common stock began trading on the Nasdaq Global Select Market under the ticker AKTS following the effectiveness of its Form S-1.
On this filings page, Stock Titan’s tools can be used to review such documents when they are available from the SEC’s EDGAR system. AI-powered summaries are designed to highlight key sections of lengthy filings, such as business descriptions, risk factors related to clinical development and radiopharmaceutical safety, and disclosures about collaborations like the company’s strategic relationship with Eli Lilly and Company.
Users interested in AKTS can use this page to monitor new filings as they appear, compare successive disclosures, and better understand how Aktis Oncology presents its radiopharmaceutical platform, pipeline candidates, and single operating segment focused on research and development in official regulatory documents.
Aktis Oncology reported 2025 results and highlighted major R&D and financing milestones. The FDA cleared Investigational New Drug applications for AKY-2519, enabling a Phase 1b trial in mid-2026, while lead program AKY-1189 continues enrolling in a Phase 1b study and received Fast Track designation in February 2026.
Cash, cash equivalents and marketable securities were $226.8 million as of December 31, 2025, with a pro forma as adjusted cash position of $562.1 million after the January 2026 IPO, which the company believes will fund operations into 2029. 2025 collaboration revenue was $6.5 million, R&D expenses were $67.5 million, G&A expenses were $13.7 million, and net loss was $63.7 million, all higher than 2024 as the pipeline and organization expanded.
Aktis Oncology is a clinical-stage company developing targeted radiopharmaceuticals built on a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes precisely to solid tumors while clearing quickly from normal tissue.
Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4–expressing tumors, including urothelial cancer, breast and lung cancers. A Phase 1b trial is under way in the United States, with preliminary dose-escalation data expected in the first quarter of 2027, and the program has FDA Fast Track Designation for locally advanced or metastatic urothelial cancer after prior systemic therapies.
The second program, [225Ac]Ac-AKY-2519, targets B7-H3–expressing tumors such as prostate and lung cancers and is moving into a Phase 1b trial after FDA clearance of related INDs. Aktis is also building an internal cGMP radiopharmaceutical facility anticipated to be operational in the second half of 2026 and has a discovery collaboration with Eli Lilly that included a $60.0 million upfront payment and eligibility for up to $1.2 billion in milestones, while retaining full rights to its own pipeline. The company highlights substantial scientific, clinical, regulatory, funding and manufacturing risks typical for an early-stage oncology platform with no approved products.
Aktis Oncology’s major venture backers report large post-IPO stakes. A group of MPM BioImpact-affiliated funds and individuals together report beneficial ownership positions in Aktis Oncology common stock, with Ansbert Gadicke associated with 10,260,064 shares, representing 19.3% of the company’s 53,296,950 shares outstanding as of the IPO prospectus. Luke Evnin is associated with 5,082,483 shares, or 9.5%, and Todd Foley with 4,237,506 shares, or 8.0%, including 2,103 stock options exercisable within 60 days.
The MPM entities are venture capital investors and acquired stakes through the IPO and automatic conversion of preferred stock. On January 12, 2026, they bought an aggregate 1,112,777 shares at $18.00 per share, for a total of $20,029,986, and also received 8,805,578 shares via preferred stock conversion at the IPO closing. The investors describe their holdings as for investment purposes, while retaining flexibility to buy or sell shares over time, and hold registration rights and are party to 180‑day IPO lock-up agreements.
EcoR1 Capital has disclosed a significant new stake in Aktis Oncology, Inc. following the company’s IPO. EcoR1 Capital, LLC reports beneficial ownership of 4,824,469 shares of common stock, representing 9.1% of the class, while its fund EcoR1 Capital Fund Qualified, L.P. holds 4,348,658 shares, or 8.2%. Oleg Nodelman, EcoR1’s manager and an Aktis director, is deemed to beneficially own 4,862,335 shares, or 9.1%, including 37,866 shares issuable under stock options granted for his board service.
The position was built through purchases of Series A and Series B redeemable convertible preferred stock totaling $32,800,000, which converted at IPO into common and Class A common shares, plus an additional 2,222,222 common shares bought in the IPO for $39,999,996. The funds also hold 1,051,412 Class A common shares that are convertible into common stock but subject to a 4.99% beneficial ownership cap. EcoR1 and Nodelman have agreed to a 180-day lock-up on sales after the offering but state they may buy or sell shares, convert Class A common stock, or use hedging strategies over time.
Eli Lilly and Company filed a Schedule 13D disclosing an 11.9% ownership stake in Aktis Oncology, Inc. following Aktis’s initial public offering. Lilly reports beneficial ownership of 6,344,114 shares of Aktis common stock, based on 53,296,950 shares outstanding after the IPO and full exercise of the underwriters’ option.
The stake comes from the conversion of preferred stock acquired for $12.0 million into 788,559 common shares at the IPO closing and the purchase of 5,555,555 shares in the IPO at $18.00 per share for about $100.0 million in cash. Lilly states it acquired the position for investment purposes, may buy or sell shares over time, and is party to an Investors’ Rights Agreement providing registration rights, as well as a 180‑day IPO lock-up restricting sales through mid‑2026.
Eli Lilly & Co filed an initial ownership report showing a significant equity position in Aktis Oncology, Inc. (AKTS). As of 01/12/2026, Eli Lilly beneficially owned 6,344,114 shares of Aktis Oncology common stock, reported as a direct holding and establishing it as a 10% owner of the company. The filing does not list any derivative securities, so the disclosed stake consists solely of common shares. This type of report is a standard regulatory disclosure of a large shareholder’s position.
Aktis Oncology director and 10% owner Todd Foley reported indirect changes in ownership tied to the company’s initial public offering. Investment funds affiliated with MPM converted preferred stock into common stock and also bought additional shares.
On January 12, 2026, 2,272,727 Series Seed, 10,227,273 Series A and 2,727,273 Series B redeemable convertible preferred shares automatically converted into 597,391, 2,688,270 and 716,872 shares of common stock, respectively, at a 3.8044-for-1 ratio with no additional payment upon the IPO closing. The affiliated funds also purchased 232,870 common shares at $18 each, bringing their indirect common stock holdings to 4,235,403 shares.
The shares are held across MPM BioVentures 2018, L.P., MPM BioVentures 2018 (B), L.P. and MPM Asset Management Investors BV2018 LLC, and the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Aktis Oncology large shareholders affiliated with MPM BioVentures 2018 reported major equity changes tied to the company’s initial public offering. On January 12, 2026, entities in the group converted Series Seed, Series A and Series B Redeemable Convertible Preferred Stock into common shares at a 3.8044-for-1 ratio, resulting in 1,314,262, 5,914,197 and 1,577,119 shares of common stock from each series, respectively. The group also reported purchasing an additional 1,112,777 common shares at $18 per share. Following these transactions, the reporting entities indirectly held a total of 10,260,064 Aktis Oncology common shares spread across several investment funds. The reporting persons state that they disclaim beneficial ownership except to the extent of their pecuniary interest.
Aktis Oncology insider funds reported major share conversions and a purchase tied to its initial public offering. On January 12, 2026, investment entities linked to MPM converted 5,000,000 Series Seed, 22,500,000 Series A and 6,000,000 Series B Redeemable Convertible Preferred Stock into common shares at a 3.8044‑for‑1 rate, issuing 1,314,262, 5,914,197 and 1,577,119 common shares, respectively.
These common shares are held across multiple MPM vehicles, including MPM Asset Management LLC, several MPM BioVentures funds, MPM Oncology funds and Oncology Impact Private Investment Fund 2, L.P. The MPM‑affiliated funds also purchased 1,112,777 shares of Aktis Oncology common stock at $18 per share, bringing their indirectly held common stock to 10,260,064 shares. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Aktis Oncology, Inc. received a large shareholder disclosure showing that Vida Ventures funds and related entities, together with director Helen Kim, beneficially own about 10.9% of the company’s common stock, based on 53,296,950 shares outstanding. Vida Ventures II, LLC holds 5,671,825 shares (10.6% of the class) and Vida Ventures II-A, LLC holds 157,387 shares (0.3%), all managed by VV Manager II, LLC.
The filing explains that these positions were built through multiple preferred stock investments in 2021–2024 that converted to common stock at the IPO, plus purchases in the offering at $18.00 per share. Helen Kim is a board member and holds 2,103 shares subject to stock options exercisable within 60 days, in addition to the Vida-related holdings. Vida II, Vida II-A and Ms. Kim have entered into 180-day lock-up agreements and hold registration and other rights under an investors’ rights agreement, while stating they may adjust their stake over time for general investment purposes.